leisure time -WSS

leisure time

author：Wikipedia 2025-09-29 14:00:24 - browse：6

AbbVie announced Tuesday that CEO Richard Gonzalez, who has managed the company’s ascent since it was spun off from the device maker Abbott Laboratories in 2013, will step down in July. Gonzalez had previously said he would depart when AbbVie had a plan in place to move on from its best-selling drug, Humira, which is now facing competition from cheaper biosimilars.

He will be replaced by Chief Operating Officer Robert Michael, who, like Gonzalez, is a longtime AbbVie executive. Gonzalez, 70, will become executive chairman of the board of directors.

Gonzalez should be a sobering reminder to the drug industry’s critics of how resilient a CEO’s reputation can be. Because while he has been a subject of nearly constant criticism for AbbVie’s handling of Humira and the patents protecting it, investors are likely to remember him fondly.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Obamacare plans could cover weight loss drugs

WSS

In 'major milestone,' FDA approves first cell therapy for solid tumors

A new drug could help frostbite victims avoid its ravages

Medical device lobby: We're tired of waiting on Medicare coverage

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

New study raises questions about niacin and heart health

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

hotspot

leisure time

hotspot

Medical leaders decry Supreme Court decision on affirmative action

Covid isolation guidance eased by the CDC

Dobbs anniversary: the lost opportunity of abortion as health care

FogPharma raises $145 million in rare Series E round

BioMarin wins approval for gene therapy to treat hemophilia A

Why getting cancer drugs just got harder for rural patients

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Drug repurposing or repositioning? The language matters

A new drug could help frostbite victims avoid its ravages

focus

Pfizer highlights cancer drugs it thinks could reignite investor interest

FDA does about

Congress may force more Covid

AstraZeneca loses challenge to Medicare drug price negotiation

Kenai launches with $82 million for Parkinson’s stem cell therapy

New CMS data security rules will hurt Medicare, Medicaid research

leisure time

focus

focus

hotspot